Johnson & Johnson (JNJ): Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
Johnson & Johnson (JNJ), headquartered in New Brunswick, New Jersey, stands as a titan in the healthcare sector, tracing its roots back to 1886. With a diverse portfolio encompassing pharmaceuticals, medical devices, and consumer health products, JNJ effectively addresses a wide spectrum of healthcare needs. The company’s Innovative Medicine segment targets critical therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular health. Meanwhile, its MedTech division offers vital interventional solutions and advanced surgical technologies. With over a century of experience, Johnson & Johnson continues to be a pivotal force in delivering innovative healthcare solutions worldwide.
Market Potential and Analyst Insights
The drug manufacturing industry, a crucial component of healthcare, is positioned for substantial growth, making JNJ a compelling investment choice. The company reported total revenues of approximately $86.58 billion, highlighting its strong financial performance driven by robust market demand for pharmaceutical products. Analysts are optimistic, projecting a target high price of $215.00 for JNJ stock, indicating significant potential for capital appreciation. The average price target stands at $172.09, with a target median price of $172.43, suggesting a concentrated positive outlook among 23 analysts who recommend a “buy.”
Currently, JNJ has a share price of $164.16, comfortably positioned between its fifty-day moving average of $160.98 and a two-week high of $168.85, indicating favorable momentum. Furthermore, with only 21,126,116 shares short—representing a mere 0.0088% of its float—investor sentiment towards JNJ remains optimistic, reflecting minimal bearish activity.
Trading Summary and Future Trends
As of today, Johnson & Johnson has approximately 2,407,239,936 shares outstanding, with a float of 2,402,838,411 shares available for trading. The company’s performance within the past year displays fluctuations, with a fifty-two-week low of $143.13 indicating potential resistance should prices decline. The current stock price of $164.16 represents a healthy trajectory compared to past performance metrics, which could foster further investor confidence moving forward.
In conclusion, the robust revenue figures coupled with positive analyst recommendations position Johnson & Johnson as an attractive investment option in the evolving healthcare landscape. As advancements in drug development gain momentum and the global healthcare demands continue to rise, JNJ’s strategic appeal will only strengthen in the coming months.
| Metric | Value |
|---|---|
| Market Cap | $395.2b |
| Total Debt | $41.5b |
| Total Cash | $25.5b |
| Shares Outstanding | 2.4b |
| Float Shares | 2.4b |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.